阿斯利康首席执行官帕斯卡尔·索里奥特表示，该公司必须以"中国速度"运营，以防止被更具创新性的竞争对手超越，避免重蹈西方汽车行业衰退的覆辙[1]。索里奥特指出，中国制药公司在抗体偶联药物和细胞疗法等新技术领域投入巨大，对欧美制药业构成潜在威胁[1]。
阿斯利康对未来增长前景保持乐观态度[1]。该公司制定了2030年实现年销售额80亿美元的增长目标，相比去年的59亿美元有显著提升[1]。在2026年上半年，阿斯利康收入达到307亿英镑，按不变汇率计算同比增长6%[1]。该公司心脏病药物瓦依努亚本月在临床试验中意外失败[1]。索里奥特表示正与英国新领导人安迪·伯纳姆政府就美英药品协议进行讨论[1]。
Pascal Soriot, chief executive of AstraZeneca, has warned that Western pharmaceutical companies must operate at a significantly faster pace to avoid falling behind more innovative competitors, particularly from China.[1] Soriot stated that the company must "move much faster," emphasizing that the organization operates according to "Chinese speed."[1] He highlighted that Chinese pharmaceutical firms are making substantial investments in emerging technologies including antibody-drug conjugates and cell therapies, posing a potential threat to European and American pharmaceutical manufacturers.[1]
AstraZeneca remains confident in its growth target of achieving $8 billion in annual sales by 2030, up from $5.9 billion in the previous year.[1] In the first half of 2026, the company reported revenues of £30.7 billion, representing 6% growth on a constant currency basis.[1] However, the company faced a setback this month when its heart disease drug Wainua unexpectedly failed in clinical trials.[1] Soriot indicated that AstraZeneca is engaged in discussions with the new UK government regarding a US-UK pharmaceutical agreement.[1]